4757 |
Patient and Device Selection for ViV TAVR: The Good, the Bad, and the Ugly |
Horst Sievert |
Aug. 07. 18 |
4756 |
MV and TV Intervention: Current Status and Future Perspectives |
Horst Sievert |
Aug. 07. 18 |
4755 |
Optimal Antithrombotic Therapy and Ongoing Clinical Trials |
Duk-Woo Park |
Aug. 07. 18 |
4754 |
TAVR for Bicuspid Valve: Clinical Outcome and Technical Considerations |
Jung-Min Ahn |
Aug. 07. 18 |
4753 |
TAVR in Low Risk Patients |
Alan C. Yeung |
Aug. 07. 18 |
4752 |
Low Gradient AS: How to Identify and Manage? |
Yong-Jin Kim |
Aug. 07. 18 |
4751 |
Management of Asymptomatic Severe AS |
Duk-Hyun Kang |
Aug. 07. 18 |
4750 |
ViV TAVR: The Role of Bioprosthetic Valve Fracture |
David Joel Cohen |
Aug. 07. 18 |
4749 |
Sapien 3 or Evolut R: Different Indications? |
Alan C. Yeung |
Aug. 07. 18 |
4748 |
CT Algorithm to Avoid Permanent Pacemaker and Para-Valvular Leakage |
Do-Yoon Kang |
Aug. 07. 18 |